Drug (ID: DG00770) and It's Reported Resistant Information
Name
Meclizine
Synonyms
Meclizine; Meclozine; 569-65-3; Parachloramine; Chiclida; Bonine; Sea-Legs; Histamethine; Histamethizine; Histametizine; Histametizyne; Bonadettes; Calmonal; Itinerol; Monamine; Navicalm; Peremesin; Postafene; Suprimal; Travelon; Vomisseis; Ancolan; Ravelon; Sabari; Siguran; Marex; Neo-istafene; Neo-suprimal; Neo-suprimel; Antivert; Vomissels; Ancolon; 1-((4-Chlorophenyl)(phenyl)methyl)-4-(3-methylbenzyl)piperazine; Meclizine hydrochloride; UCB 5062; Bonamine; Diadril; UCB 170; U.C.B. 5062; 1-[(4-chlorophenyl)-phenylmethyl]-4-[(3-methylphenyl)methyl]piperazine; 1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine; Postafen; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)diethylenediamine; NSC 169189; UCB 5052; Piperazine, 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-; U. C. B. 5062; CHEBI:6709; (+-)-Meclizine; Piperazine, 1-(p-chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)-; Dramamine II; Piperazine, 1-((4-chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)-; 1-(p-Chlorobenzhydryl)-4-(m-methylbenzyl)piperazine; NSC-169189; Meclozina; Meclozinum; Subari; 1-(p-Chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)piperazine; Piperazine,1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)methyl]-; Meclizine [INN:BAN]; Meclozinum [INN-Latin]; Meclozina [INN-Spanish]; 1-[(4-Chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine; Piperazine, 1-(p-chloro-.alpha.-phenylbenzyl)-4-(m-methylbenzyl)-; Nevidoxine (TN); Meclozine (BAN); Meclozine [INN]; HSDB 3113; EINECS 209-323-3; 1-p-Chlorobenzhydryl-4-m-methylbenzylpiperazine; BRN 0332002; Meclozin; 1-(p-Chloro-alpha-phenylbenzyl)-4-(m-methylbenzyl)piperazine; 1-((4-Chlorophenyl)phenylmethyl)-4-((3-methylphenyl)methyl)piperazine; Diadril (Salt/Mix); Bonamine (Salt/Mix); Bonadoxin (Salt/Mix); Vertizine (Salt/Mix); Spectrum_000891; (.+/-.)-Meclizine; Prestwick0_000457; Prestwick1_000457; Prestwick2_000457; Prestwick3_000457; Spectrum2_000110; Spectrum3_000485; Spectrum4_000037; Spectrum5_000919; SCHEMBL4649; CHEMBL1623; BSPBio_000534; BSPBio_001949; KBioGR_000473; KBioSS_001371; 4-Methyl-2-chloroacetophenone; DivK1c_000407; SPBio_000100; SPBio_002473; BPBio1_000588; GTPL2757; DTXSID0023242; BDBM81467; KBio1_000407; KBio2_001371; KBio2_003939; KBio2_006507; KBio3_001449; NINDS_000407; Meclizine;Meclozine; Parachloramine; BCP28339; NSC_4034; MFCD00242697; NSC169189; AKOS015951354; DB00737; MCULE-7463916552; IDI1_000407; NCGC00018296-02; NCGC00018296-04; NCGC00018296-08; BS-17628; CAS_569-65-3; SBI-0051433.P003; WLN: T6N DNTJ AYR&R DG& D1R C1; AB00053493; FT-0659103; EN300-58334; C07116; D08163; D81963; AB00053493_14; AB00053493_15; L001136; Q386441; BRD-A50311610-300-05-4; BRD-A50311610-300-06-2; Z53003552; 1-[(4-Chlorophenyl)(phenyl)methyl]-4-(3-methylbenzyl)piperazine #
    Click to Show/Hide
Indication
In total 1 Indication(s)
Dizziness [ICD-11: MB48]
Phase 1
[1]
Structure
Target . NOUNIPROTAC [1]
Click to Show/Hide the Molecular Information and External Link(s) of This Drug
Formula
C25H27ClN2
IsoSMILES
CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl
InChI
1S/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3
InChIKey
OCJYIGYOJCODJL-UHFFFAOYSA-N
PubChem CID
4034
TTD Drug ID
D0QO9G
VARIDT ID
DR00977
INTEDE ID
DR1006
DrugBank ID
DB00737
Type(s) of Resistant Mechanism of This Drug
  UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Click to Show/Hide the Resistance Disease of This Class
Brain cancer [ICD-11: 2A00]
Click to Show/Hide
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Unusual Activation of Pro-survival Pathway (UAPP) Click to Show/Hide
Key Molecule: Serine/threonine-protein kinase mTOR (mTOR) [1]
Molecule Alteration Expression
Down-regulation
Sensitive Disease Glioblastoma multiforme [ICD-11: 2A00.03]
Experimental Note Revealed Based on the Cell Line Data
In Vitro Model SH-1-V4 cells Esophagus Homo sapiens (Human) N.A.
Experiment for
Molecule Alteration
Western blotting analysis
Mechanism Description GBM stem cells (GBMSC) resist the standard-of-care therapy, temozolomide, and are considered a major contributor to tumor resistance. GBMSCs are resistant to the standard-of-care temozolomide therapy, but temozolomide supplemented with tight-binding piperazine meclizine and flunarizine greatly enhanced GBMSC death over temozolomide alone.
References
Ref 1 Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells .Pharmaceuticals (Basel). 2020 Nov 24;13(12):419. doi: 10.3390/ph13120419. 10.3390/ph13120419

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.